The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 28, 2022
Filed:
Jan. 25, 2016
Applicant:
Curevac Ag, Tubingen, DE;
Inventors:
Assignee:
CureVac AG, Tübingen, DE;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C12N 15/67 (2006.01); A61K 47/54 (2017.01); A61K 47/64 (2017.01); A61K 38/19 (2006.01); A61K 39/00 (2006.01); C07K 14/005 (2006.01); C07K 14/47 (2006.01); G16B 20/50 (2019.01); A61K 39/145 (2006.01); A61K 39/108 (2006.01); C07K 14/245 (2006.01); C12N 7/00 (2006.01); C12N 15/11 (2006.01); A61K 38/18 (2006.01); A61K 38/28 (2006.01); A61K 39/12 (2006.01); A61K 39/21 (2006.01); A61K 38/17 (2006.01); G16B 20/00 (2019.01); G16B 30/00 (2019.01);
U.S. Cl.
CPC ...
A61K 48/005 (2013.01); A61K 38/1735 (2013.01); A61K 38/1816 (2013.01); A61K 38/19 (2013.01); A61K 38/193 (2013.01); A61K 38/28 (2013.01); A61K 39/00 (2013.01); A61K 39/0011 (2013.01); A61K 39/00117 (2018.08); A61K 39/001106 (2018.08); A61K 39/001153 (2018.08); A61K 39/001156 (2018.08); A61K 39/001184 (2018.08); A61K 39/001186 (2018.08); A61K 39/001188 (2018.08); A61K 39/001189 (2018.08); A61K 39/001191 (2018.08); A61K 39/001192 (2018.08); A61K 39/001194 (2018.08); A61K 39/001197 (2018.08); A61K 39/0258 (2013.01); A61K 39/12 (2013.01); A61K 39/145 (2013.01); A61K 39/21 (2013.01); A61K 47/542 (2017.08); A61K 47/6455 (2017.08); A61K 48/0066 (2013.01); A61K 48/0075 (2013.01); A61K 48/0083 (2013.01); C07K 14/005 (2013.01); C07K 14/245 (2013.01); C07K 14/4727 (2013.01); C07K 14/4748 (2013.01); C12N 7/00 (2013.01); C12N 15/11 (2013.01); C12N 15/67 (2013.01); G16B 20/50 (2019.02); A61K 48/00 (2013.01); A61K 2039/53 (2013.01); C12N 2310/334 (2013.01); C12N 2310/336 (2013.01); C12N 2740/16022 (2013.01); C12N 2740/16034 (2013.01); C12N 2760/14122 (2013.01); C12N 2760/14134 (2013.01); C12N 2760/16022 (2013.01); C12N 2760/16034 (2013.01); C12N 2760/16071 (2013.01); C12N 2770/24122 (2013.01); C12N 2770/24134 (2013.01); G16B 20/00 (2019.02); G16B 30/00 (2019.02); Y02A 50/30 (2018.01);
Abstract
The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.